{"filing":{"accession_number":"0001628280-26-051399","cik":"0001842952","ticker":"CNTX","company_name":"Context Therapeutics Inc.","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-29","primary_document":"cntx-20260729.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1842952/000162828026051399/cntx-20260729.htm"},"events":[{"id":22384,"run_id":20247,"accession_number":"0001628280-26-051399","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Context Therapeutics received written notice from Nasdaq on July 29, 2026, that it failed to maintain the minimum closing bid price of $1.00 per share for 30 consecutive business days, triggering non-compliance with Nasdaq Listing Rule 5550(a)(2). The company has until January 25, 2027, to regain compliance or faces potential delisting, with the possibility of a second 180-day cure period if it meets Capital Market listing standards. This is a classic delisting-risk disclosure under Item 3.01.","company_name":"Context Therapeutics Inc.","ticker":"CNTX","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":[{"id":22308,"accession_number":"0001628280-26-051399","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Context Therapeutics received written notice from Nasdaq on July 29, 2026, that it failed to maintain the minimum closing bid price of $1.00 per share for 30 consecutive business days, triggering non-compliance with Nasdaq Listing Rule 5550(a)(2). The company has until January 25, 2027, to regain compliance or faces potential delisting, with the possibility of a second 180-day cure period if it meets Capital Market listing standards. This is a classic delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:11:14.965376+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22308,"accession_number":"0001628280-26-051399","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Context Therapeutics received written notice from Nasdaq on July 29, 2026, that it failed to maintain the minimum closing bid price of $1.00 per share for 30 consecutive business days, triggering non-compliance with Nasdaq Listing Rule 5550(a)(2). The company has until January 25, 2027, to regain compliance or faces potential delisting, with the possibility of a second 180-day cure period if it meets Capital Market listing standards. This is a classic delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:11:14.965376+00:00","company_name":"Context Therapeutics Inc.","ticker":"CNTX","filing_date":"2026-07-31"}]}